Chiasma has completed patient enrolment in the MPOWERED trial, a Phase lll clinical study of octreotide capsules to treat patients with acromegaly.

A total of 135 acromegaly patients have been enrolled in the global, randomised, open-label and active-controlled, 15-month trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Approximately 80 patients who respond to octreotide capsules after a six-month run-in period will be randomised to receive either octreotide capsules or injectable somatostatin receptor ligands (octreotide or lanreotide), and then followed for an additional nine months.

The trial is expected to analyse the proportion of patients who maintain their biochemical response to octreotide capsules and patient-reported outcomes in patients treated with octreotide capsules, compared to patients treated with standard of care injectable somatostatin receptor ligands.

Scheduled to be completed by the last quarter of next year, the MPOWERED trial aims to provide top-line results in early 2020.

“We are making significant progress as we seek to advance octreotide capsules as a maintenance treatment for adult patients with acromegaly.”

The trial is set to support Chiasma to obtain regulatory approval in European Union for the octreotide capsule.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chiasma president and CEO Mark Fitzpatrick said: “We are making significant progress as we seek to advance octreotide capsules as a maintenance treatment for adult patients with acromegaly.

“If approved, octreotide capsules will provide these patients with an oral alternative to the current standard of care, injectable somatostatin analogs.”

Octreotide capsules are currently being investigated as a new oral drug for use as a maintenance therapy of adult patients with acromegaly.

Acromegaly is commonly caused by a benign tumour of the pituitary gland that produces an additional growth hormone (GH), thereby eventually leading to significant health problems and early death if untreated.